Alzheimer's Disease Diagnosis in Motion - Bringing Plasma pTau 217 from Validation to Clinical Practice
This was the third in a series of live webinars dedicated to promising neuro biomarkers.
Watch the replay below.
Bringing Plasma pTau 217 from Validation to Clinical Practice
In this edition of the Neuro Biomarker Talks - From Discovery to Diagnostic Impact, Dr. Daniel Alcolea and Prof. Dr. Jonathan Schott will discuss how the scientific advances and evidence supporting plasma pTau 217 are being translated into clinical practice, helping to optimize the Alzheimer's disease diagnostic pathway through more accessible and timely diagnosis.
The webinar is moderated by Dr. Nathalie Le Bastard, Strategic and Scientific Affairs Manager, Fujirebio Europe.
The speakers
Dr. Daniel Alcolea
Neurologist and researcher at Hospital Sant Pau in Barcelona, Spain. His clinical work focuses on the evaluation, diagnosis and treatment of patients with memory disorders, while his research centers around the discovery and development of fluid biomarkers for the early and accurate diagnosis of neurodegenerative diseases.
Dr. Daniel Alcolea's Neuro Biomarker Talk:
Building confidence in blood-based biomarkers: clinical validation of a plasma pTau 217 assay
Prof. Dr. Jonathan Schott
Professor of Neurology at University College London and Consultant Neurologist at University College London Hospitals. His work focuses on dementias and ageing, with particular expertise in integrating clinical assessments, imaging, and fluid biomarkers to improve differential diagnosis and facilitate earlier detection of Alzheimer's disease.
Dr. Jonathan Schott's Neuro Biomarker Talk:
Performance and clinical use of plasma pTau 217 - the UCLH experience
Watch the replay video below
For whom this webinar is intended
This session is particularly relevant for laboratory and healthcare professionals involved in clinical care as well as clinical and pharmaceutical research, with a focus on Alzheimer’s disease diagnosis and related disorders.
